Clinical Trial Update: Pharmacokinetic Study of 4 mg Nicotine Lozenge. [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetic study of a 4 mg nicotine lozenge for smoking cessation completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• Nicotine lozenge 4 mg (nicotine lozenge)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Smoking Cessation | Phase 2 | Status: COMPLETED | Results posted: 2015-01-22